These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10522695)

  • 21. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
    Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
    J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
    Benjahad A; Courté K; Guillemont J; Mabire D; Coupa S; Poncelet A; Csoka I; Andries K; Pauwels R; de Béthune MP; Monneret C; Bisagni E; Nguyen CH; Grierson DS
    J Med Chem; 2004 Oct; 47(22):5501-14. PubMed ID: 15481987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz.
    Bosch RJ; Downey GF; Katzenstein DA; Hellmann N; Bacheler L; Albrecht MA;
    AIDS; 2003 Nov; 17(16):2395-6. PubMed ID: 14571193
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
    Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
    Jin K; Sang Y; Han S; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2019 Aug; 176():11-20. PubMed ID: 31091477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Duchowicz PR; Fernández M; Caballero J; Castro EA; Fernández FM
    Bioorg Med Chem; 2006 Sep; 14(17):5876-89. PubMed ID: 16766190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
    Costa CCP; Boechat N; Bastos MM; da Silva FC; Marttorelli A; Souza TML; Baptista MS; Hoelz LVB; Cafffarena ER
    Curr Top Med Chem; 2018; 18(17):1494-1505. PubMed ID: 30370848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and Anti-HIV-1 Evaluation of Some Novel MC-1220 Analogs as Non-Nucleoside Reverse Transcriptase Inhibitors.
    Loksha YM; Pedersen EB; Loddo R; La Colla P
    Arch Pharm (Weinheim); 2016 May; 349(5):363-72. PubMed ID: 26996241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro.
    Albright AV; Erickson-Viitanen S; O'Connor M; Frank I; Rayner MM; González-Scarano F
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1527-37. PubMed ID: 11054266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
    Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
    AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Murugesan V; Makwana N; Suryawanshi R; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Katti SB
    Bioorg Med Chem; 2014 Jun; 22(12):3159-70. PubMed ID: 24794742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Sahlberg C; Noréen R; Engelhardt P; Högberg M; Kangasmetsä J; Vrang L; Zhang H
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1511-6. PubMed ID: 9873380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
    Jiang T; Kuhen KL; Wolff K; Yin H; Bieza K; Caldwell J; Bursulaya B; Wu TY; He Y
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2105-8. PubMed ID: 16480865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Balzarini J; Gago F
    J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
    Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
    J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.